Follow
Seyed Ali Jazayeri-Tehrani
Seyed Ali Jazayeri-Tehrani
MD, PhD. in Nutritional Sciences
Verified email at farabi.tums.ac.ir
Title
Cited by
Cited by
Year
Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind …
SA Jazayeri-Tehrani, SM Rezayat, S Mansouri, M Qorbani, SM Alavian, ...
Nutrition & metabolism 16, 1-13, 2019
1502019
Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled …
M Daneshi-Maskooni, SA Keshavarz, M Qorbani, S Mansouri, SM Alavian, ...
Nutrition & metabolism 15, 1-12, 2018
512018
Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind …
M Daneshi-Maskooni, SA Keshavarz, M Qorbani, S Mansouri, SM Alavian, ...
BMC complementary and alternative medicine 19, 1-11, 2019
452019
The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and …
M Daneshi-Maskooni, SA Keshavarz, S Mansouri, M Qorbani, SM Alavian, ...
Trials 18, 1-9, 2017
382017
Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a …
SA Jazayeri-Tehrani, SM Rezayat, S Mansouri, M Qorbani, SM Alavian, ...
BMJ open 7 (7), e016914, 2017
332017
The nanocurcumin reduces appetite in obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial
SA Jazayeri-Tehrani, SM Rezayat, S Mansouri, M Qorbani, SM Alavian, ...
Nanomedicine Journal 5 (2), 67-76, 2018
242018
Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: Study protocol for a randomized double-blind clinical trial
F Naeini, Z Namkhah, H Tutunchi, SM Rezayat, S Mansouri, ...
Trials 22, 1-9, 2021
92021
ریسک فاکتورهای مرگ بعد از عمل Coronary artery bypass graft بیمارستان امام، 78-1375
حسن رادمهر, زینت حتمی, سیدعلی جزایری طهرانی, آیت اله بیاتیان
مجله دانشکده پزشکی دانشگاه علوم پزشکی تهران 60 (3), 242-247, 2002
12002
Milad Daneshi-Maskooni1, 2, Seyed Ali Keshavarz3, Mostafa Qorbani4, Siavash Mansouri5, Seyed Moayed Alavian6
M Badri-Fariman, SA Jazayeri-Tehrani, G Sotoudeh
2019
Milad Daneshi-Maskooni1, Seyed Ali Keshavarz2, Siavash Mansouri3, Mostafa Qorbani4, Seyed Moayed Alavian5
M Badri-Fariman, SA Jazayeri-Tehrani, G Sotoudeh
2017
Seyed Ali Jazayeri-Tehrani, Seyed Mahdi Rezayat, 2, 3, 4 Siavash Mansouri, 5 Mostafa Qorbani, 6 Seyed Moayed Alavian, 7 Milad Daneshi-Maskooni, 8
MJ Hosseinzadeh-Attar
The system can't perform the operation now. Try again later.
Articles 1–11